메뉴 건너뛰기




Volumn 111, Issue 11, 2014, Pages 2067-2075

Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: The phase II RACHEL study

(17)  Van Cutsem, E a   Li, C P b,c   Nowara, E d   Aprile, G e   Moore, M f   Federowicz, I g   Van Laethem, J L h   Hsu, C i   Tham, C K j   Stemmer, S M k   Lipp, R l   Zeaiter, A m   Fittipaldo, A m   Csutor, Z n   Klughammer, B n   Meng, X o   Ciuleanu, T p  


Author keywords

dose; epidermal growth factor; erlotinib; oncology; pancreatic cancer; rash

Indexed keywords

ERLOTINIB; GEMCITABINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR; QUINAZOLINE DERIVATIVE;

EID: 84927176540     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.494     Document Type: Article
Times cited : (33)

References (27)
  • 1
    • 84867035474 scopus 로고    scopus 로고
    • Association between skin toxicities and treatment outcomes in patients with pancreatic cancer (PC) receiving erlotinib (E): Memorial Sloan-Kettering Cancer Center (MSKCC) experience
    • Abstract 294
    • Alejandro LM, Adel NG, O'Reilly EM, Riedel E, Lacouture ME (2012) Association between skin toxicities and treatment outcomes in patients with pancreatic cancer (PC) receiving erlotinib (E): Memorial Sloan-Kettering Cancer Center (MSKCC) experience. J Clin Oncol 30: Abstract 294.
    • (2012) J Clin Oncol , vol.30
    • Alejandro, L.M.1    Adel, N.G.2    O'reilly, E.M.3    Riedel, E.4    Lacouture, M.E.5
  • 3
  • 5
    • 43549094700 scopus 로고    scopus 로고
    • New therapeutic directions for advanced pancreatic cancer: Targeting the epidermal growth factor and vascular endothelial growth factor pathways
    • Burris H 3rd, Rocha-Lima C (2008) New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. Oncologist 13: 289-298.
    • (2008) Oncologist , vol.13 , pp. 289-298
    • Burris, H.1    Rocha-Lima, C.2
  • 8
    • 78650095716 scopus 로고    scopus 로고
    • Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3
    • da Cunha Santos G, Dhani N, Tu D, Chin K, Ludkovski O, Kamel-Reid S, Squire J, Parulekar W, Moore MJ, Tsao MS (2010) Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. Cancer 116: 5599-5607.
    • (2010) Cancer , vol.116 , pp. 5599-5607
    • Da Cunha Santos, G.1    Dhani, N.2    Tu, D.3    Chin, K.4    Ludkovski, O.5    Kamel-Reid, S.6    Squire, J.7    Parulekar, W.8    Moore, M.J.9    Tsao, M.S.10
  • 9
    • 77954216241 scopus 로고    scopus 로고
    • Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib
    • Guttman-Yassky E, Mita A, De Jonge M, Matthews L, McCarthy S, Iwata KK, Verweij J, Rowinsky EK, Krueger JG (2010) Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. Eur J Cancer 46: 2010-2019.
    • (2010) Eur J Cancer , vol.46 , pp. 2010-2019
    • Guttman-Yassky, E.1    Mita, A.2    De Jonge, M.3    Matthews, L.4    McCarthy, S.5    Iwata, K.K.6    Verweij, J.7    Rowinsky, E.K.8    Krueger, J.G.9
  • 10
    • 77954786770 scopus 로고    scopus 로고
    • First-line treatment of metastatic pancreatic adenocarcinoma: Can we do better?
    • Merl MY, Abdelghany O, Li J, Saif MW (2010) First-line treatment of metastatic pancreatic adenocarcinoma: can we do better? JOP 11: 317-320.
    • (2010) JOP , vol.11 , pp. 317-320
    • Merl, M.Y.1    Abdelghany, O.2    Li, J.3    Saif, M.W.4
  • 13
    • 63449142391 scopus 로고    scopus 로고
    • Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy
    • Peeters M, Siena S, Van Custem E, Sobrero A, Hendlisz A, Cascinu S, Kalofonos H, Devercelli G, Wolf M, Amado RG (2009) Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer 115: 1544-1554.
    • (2009) Cancer , vol.115 , pp. 1544-1554
    • Peeters, M.1    Siena, S.2    Van Custem, E.3    Sobrero, A.4    Hendlisz, A.5    Cascinu, S.6    Kalofonos, H.7    Devercelli, G.8    Wolf, M.9    Amado, R.G.10
  • 14
    • 84921349038 scopus 로고    scopus 로고
    • Cutaneous toxicity secondary to erlotinib therapy in patients with non-small cell lung cancer in the NCIC CTG BR.21 study: Time course and correlation with survival
    • Abstract 7573
    • Perez-Soler R, Leon L, Wojtowicz-Praga S (2012) Cutaneous toxicity secondary to erlotinib therapy in patients with non-small cell lung cancer in the NCIC CTG BR.21 study: time course and correlation with survival. J Clin Oncol 30: Abstract 7573.
    • (2012) J Clin Oncol , vol.30
    • Perez-Soler, R.1    Leon, L.2    Wojtowicz-Praga, S.3
  • 15
    • 36549083856 scopus 로고    scopus 로고
    • Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study
    • Abstract LBA4509
    • Philip PA, Benedetti J, Fenoglio-Preiser C, Zalupski M, Lenz H, O'Reilly E, Wong R, Atkins J, Abruzzese J, Blanke C (2007) Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. J Clin Oncol 25: Abstract LBA4509.
    • (2007) J Clin Oncol , vol.25
    • Philip, P.A.1    Benedetti, J.2    Fenoglio-Preiser, C.3    Zalupski, M.4    Lenz, H.5    O'reilly, E.6    Wong, R.7    Atkins, J.8    Abruzzese, J.9    Blanke, C.10
  • 18
    • 0344773402 scopus 로고    scopus 로고
    • The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies
    • Abstract 817
    • Saltz L, Kies M, Abbruzzese L, Needle M (2003) The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 22: Abstract 817.
    • (2003) Proc Am Soc Clin Oncol , vol.22
    • Saltz, L.1    Kies, M.2    Abbruzzese, L.3    Needle, M.4
  • 25
    • 77249151146 scopus 로고    scopus 로고
    • Rash as a marker for efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: Results from the AViTA study
    • Abstract 4532
    • Verslype C, Vervenne W, Bennouna J, Humblet Y, Cosaert J, Van Cutsem E (2009) Rash as a marker for efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: results from the AViTA study. J Clin Oncol 27: Abstract 4532.
    • (2009) J Clin Oncol , vol.27
    • Verslype, C.1    Vervenne, W.2    Bennouna, J.3    Humblet, Y.4    Cosaert, J.5    Van Cutsem, E.6
  • 26
    • 34447129570 scopus 로고    scopus 로고
    • Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies
    • Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ (2007) Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 13: 3913-3921.
    • (2007) Clin Cancer Res , vol.13 , pp. 3913-3921
    • Wacker, B.1    Nagrani, T.2    Weinberg, J.3    Witt, K.4    Clark, G.5    Cagnoni, P.J.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.